Genus
2300p
-10.0 -0.4%
market vs.
industry Growth & Value
| 12m Forecast Rolling | ||||
| PE Ratio (f) | 29.2 |
|
|
|
| PEG Ratio (f) |
|
|
||
| EPS Growth (f) | % |
|
|
|
| Dividend Yield (f) | % |
|
|
|
| Valuation (ttm) | ||||
| Price to Book Value | 3.42 |
|
|
|
| Price to Tang. Book |
|
|
||
| Price to Free Cashflow |
|
|
||
| Price to Sales |
|
|
||
| EV to EBITDA |
|
|
||
market vs.
industry Quality
| Year End 30th Jun | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019E | 2020E | CAGR / Avg | |
| Revenue | £m | |||||||||
| Operating Profit | £m | |||||||||
| Net Profit | £m | |||||||||
| EPS Reported | p | |||||||||
| EPS Normalised | p | |||||||||
| EPS Growth | % | |||||||||
| PE Ratio | x | |||||||||
| PEG | x | |||||||||
| Profitability | ||||||||||
| Operating Margin | % | |||||||||
| ROA | % | |||||||||
| ROCE | % | |||||||||
| ROE | % | |||||||||
| Cashflow | ||||||||||
| Op. Cashflow ps | p | |||||||||
| Capex ps | p | |||||||||
| Free Cashflow ps | p | |||||||||
| Last ex-div: 15th Nov, paid: 30th Nov more... Dividends | ||||||||||
| Dividend ps | p | |||||||||
| Dividend Growth | % | |||||||||
| Dividend Yield | % | |||||||||
| Dividend Cover | x | |||||||||
| Balance Sheet | ||||||||||
| Cash etc | £m | |||||||||
| Working Capital | £m | |||||||||
| Net Fixed Assets | £m | |||||||||
| Net Debt | £m | |||||||||
| Book Value | £m | |||||||||
| Average Shares | m | |||||||||
| Book Value ps | p | +6.4% | ||||||||
| Leverage (ttm) | Total | -Intang | +Pension | ||
| Gross Gearing | % | ||||
| Net Gearing | % | ||||
| Cash / Assets | % |
| Liquidity (ttm) | ||
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | |
| Asset Turnover | |
| Rec's Turnover | |
| Stock Turnover | |
market vs.
industry Recent History
| Latest interim period (ended 30th Jun '18) vs. prior year | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| 3yr Compound Annual Growth Rate | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| DPS Growth | % |
|
|
|
Broker Consensus Trend
| Recommendation: | Strong Sell | Sell | Hold | Buy | Strong Buy |
|---|---|---|---|---|---|
| No. of Analysts: | 0 | 0 | 6 | 0 | 0 |
Genus plc is an animal genetics company, which provides farmers with genetics that enable them to produce animal protein, in the form of meat and milk. The Company's segments include Genus PIC, Genus ABS, Genus Asia, and Research and Development. The Genus PIC segment is engaged in porcine sales business, excluding Asia, and serves porcine customers in North America, Latin America and Europe. The Genus ABS segment is engaged in bovine sales business, excluding Asia, and serves dairy and beef customers in North America, Latin America and Europe. The Genus Asia segment is engaged in porcine and bovine business in Asia, and serves porcine, dairy and beef customers in Asian markets. In the porcine market, it sells boars and sows. In the dairy and beef markets, its primary product is bull semen. The Company offers embryos through its subsidiary, In Vitro Brasil S.A. Its porcine business has a network of over 600 breeding herds in approximately 40 countries.
Directors: Karim Bitar (CEO) , Stephen Wilson (FID) , Jonathan Lightner (CSO) , Dan Hartley (GCN) , Angelle Rosata (DHR) , Bill Christianson (OTH) , Jerry Thompson (OTH) , Nate Zwald (OTH) , Robert Lawson (NEC) 72, Ian Charles (NED) , Lysanne Gray (NED) , Lesley Knox (NED) 64, Duncan Maskell (NED) ,
No. of Employees: 2,787 No. of Shareholders: n/a
| Last Annual | June 30th, 2018 |
| Last Interim | June 30th, 2018 |
| Incorporated | September 26, 1994 |
| Public Since | July 6, 2000 |
| Shares in Issue | 61,945,941 |
| Free Float | 61.0m (98.4%) |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | FTSE All Share , FTSE All Share Health Care , FTSE All Share Pharmaceuticals & Biotechnology , FTSE 350 , FTSE 350 Lower Yield , FTSE 250 , FTSE 350 Pharmaceuticals & Biotechnology , FTSE Techmark Focus , FTSE Techmark All Share , , |
| Exchange |
London Stock Exchange (Full)
|
| Eligible for | an ISA? a SIPP? |
| Address | Matrix House Basing View, BASINGSTOKE, RG21 4DZ, United Kingdom |
| Web | https://www.genusplc.com |
| Phone | +44 1256 347100 |
| Contact | Charles Ryland (IR Contact Officer) |
| Auditors | Deloitte LLP |
| 12th Oct | Genus - Annual Report and Annual General Meeting |
| 12th Oct | Genus - Director/PDMR Shareholding |
| 12th Oct | Genus - Director/PDMR Shareholding |
| 1st Oct | Genus - Total Voting Rights |
| 24th Sep | Genus - Additional Listing |
Recent ↓
Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2018.
